Saturday , August 19 2017
Home / Business News / Johnson & Johnson Ends Takeover Discussions with Actelion Pharmaceuticals

Johnson & Johnson Ends Takeover Discussions with Actelion Pharmaceuticals

NEW BRUNSWICK, N.J., Dec. 13, 2016 /PRNewswire/ — Johnson & Johnson (NYSE: JNJ) today confirmed it has ended discussions with Actelion Pharmaceuticals Ltd. (SIX: ATLN) regarding a potential transaction. Johnson & Johnson was not able to reach an agreement that it believed would create adequate value for its shareholders.

 

About Johnson & Johnson

Caring for the world, one person at a time, inspires and unites the people of Johnson & Johnson. We embrace research and science – bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 126,900 employees at more than 250 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

Check Also

Fluidigm Licenses CFTR NGS Assay from Baylor Genetics for Use with the Juno System

SOUTH SAN FRANCISCO, Calif., Aug. 17, 2017 (GLOBE NEWSWIRE) — Fluidigm Corporation (NASDAQ:FLDM) and Baylor …